Thursday Adult ADHD Peer-led Support Group

Adult ADHD Surge

Adult ADHD has seen a sharp rise in diagnoses over the past five years, driven by greater public awareness and the lingering effects of the COVID-19 pandemic. From 2020 to 2023, new cases increased following a prior decline, with factors like remote work exposing concentration issues and social media amplifying symptoms. Globally, persistent ADHD affects 6.76% of adults, or about 366 million people, with U.S. figures hitting 15.5 million. Women, often underdiagnosed due to subtler presentations like internal restlessness rather than hyperactivity, now account for much of the growth.

Medication shortages compound these challenges, with stimulants like Adderall and Ritalin in short supply since 2022. The U.S. Drug Enforcement Administration raised production quotas in 2025, but disruptions persist into 2026 due to manufacturing delays and raw ingredient constraints. Over 71% of adults on stimulants reported filling difficulties in 2023 surveys, leading to forced switches to alternatives like non-stimulants or generics, which can cost hundreds more monthly and vary in efficacy. Untreated, symptoms escalate: impulsivity fuels road rage—ADHD drivers face 1.5 times higher crash risks—and workplace conflicts, with dismissal rates double those of neurotypical peers.

Beyond access, emotional impulsivity emerges as a core, underappreciated hurdle. Research shows 50-70% of ADHD children face peer rejection by second grade, a pattern persisting into adulthood where quick anger erodes friendships and partnerships. Hormonal fluctuations in women exacerbate mood swings, linking ADHD to higher rates of anxiety and depression. Trade-offs abound: while new 2025 U.S. guidelines from APSARD aim to standardize adult care, debates rage over potential overdiagnosis amid stable prevalence rates, pitting patient advocates against regulators wary of diversion.

Support networks offer a counterbalance, with peer-led groups providing validation and strategies absent in strained clinical settings. Conferences like ADHD ICONnect in February 2026 highlight community-driven approaches, emphasizing task-focused management over symptom checklists. Yet tensions remain between personalized treatments—emerging trends like neurofeedback—and systemic barriers, including inconsistent GP prescribing rights across states.